The prognostic role of tumor-infiltrating tryptase 1 mast cells in human solid tumors remains controversial. Herein, we conducted a meta-analysis including 28 published studies with 4224 patients identified from PubMed and EBSCO to assess the prognostic impact of tumor-infiltrating tryptase 1 mast cells in human solid tumors. We found that tryptase 1 mast cell infiltration significantly decreased overall survival (OS) and disease-free survival (DFS) in all types of solid tumors. In stratified analyses, tryptase 1 mast cell infiltration was significantly associated with worse OS in non-small cell lung cancer, hepatocellular carcinoma and 5-year survival in colorectal cancer. And these cells were inversely associated with DFS in hepatocellular and colorectal cancer. In addition, high density of intratumoral tryptase 1 mast cells significantly correlated with lymph node metastasis of solid tumor. In conclusion, Tryptase 1 mast cell infiltration leads to an unfavorable clinical outcome in solid tumors, implicating that it is a valuable biomarker for prognostic prediction for human solid malignances and targeting it may have a potential for effective treatment.
Mast cells exert a variety of roles in regulating inflammatory process, tissue remodeling and host defense. These cells are often activated by multiple stimuli including certain cytokines and tolllike receptors in the context of tumor microenvironment. 1 Accumulating evidence has demonstrated tumor-infiltrating activated mast cells were significantly associated with progression of solid tumors through various mechanisms including promoting angiogenesis and immune suppression. 2 Tryptase, the most abundant secretory granule-derived neutral serine proteinase contained in mast cells, can degrade components of the extracellular matrix and has been used as a specific marker for mast cells. Tryptase can finely represent the activation status of mast cells. 3 Tryptase 1 mast cells are often among the first immune cells recruited to tumor sites in response to the chemotactic stimuli and increase in solid tumors. 4 Recent studies have associated tumor-infiltrating tryptase 1 mast cells and cancer prognosis, but their results were controversial. 5 Therefore, an in-depth assessment is warranted. Furthermore, the potential of these cells as an effective biomarker in prognostic prediction and targeted therapy is necessary to be explored.
Herein, we performed this meta-analysis to test overall survival (OS) and disease-free survival (DFS) as outcomes in patients with solid tumor with known intratumoral tryptase 1 mast cell density. The aim of this study was to quantitatively summarize the association between tryptase 1 mast cell infiltration and clinical outcomes in patients with solid tumor, and thereby provided more evidence on the clinical value of tumor-infiltrating tryptase 1 mast cells as a prognostic biomarker for solid malignances.
Material and Methods

Search strategy
We 
Quality assessment
The studies included in the meta-analysis were cohort studies. The quality of each included study was assessed using Newcastle-Ottawa scale (NOS) by two independent authors. 6 The studies with 6 scores or more were classified as high quality studies. A consensus NOS score for each item was achieved.
Statistical analysis
Extracted data were combined into a meta-analysis using STATA 12.0 analysis software (Stata Corporation, College Station, TX). Statistical heterogeneity was assessed using the chi-squared based Q-test or the I 2 method. 7 Data were combined according to the random-effect model in the presence of heterogeneity, 8 otherwise, the fixed-effect model was performed. 9 Sensitivity analysis was employed to assess the influence of each study on the pooled result. Begg's funnel plot and Egger's test 10 were calculated to investigate potential publication bias. All p values were two-sided and <0.05 are considered statistically significant.
Result
Search results and description of studies
Literature searches yield 11,417 records and the results were shown in Figure S1 . Twenty eight studies containing 4,224 patients with solid tumor were identified for the assessment of tumor-infiltrating tryptase 1 mast cells. All the studies were evaluated by the Newcastle-Ottawa Scale (NOS), and were in accordance with the inclusion criteria and suitable for data consolidation. Characteristics of included studies for OS, DFS and clinicopathological features such as TNM stage, tumor differentiation and so forth were shown in Table 1 and Table S1 , respectively.
Meta-analyses
Overall survival. The meta-analysis showed that tryptase In this meta-analysis the authors found that patients whose tumors had tryptase1 mast-cell infiltration had significantly decreased survival, especially in NSCLC, HCC and CRC. In addition, increased density of these cells was significantly associated with lymph node metastasis. They may thus offer a valuable prognostic biomarker and a potential therapeutic target. Tumor Immunology and Microenvironment (Fig. 3 ) By the way, there was only one study reporting the relevant data for OS in breast, ovarian, cervical, pancreatic cancer and malignant pleural mesothelioma, respectively, thus, we could not get a combined result for them.
Disease-free survival. Meta-analysis showed that tryptase 1 mast cell infiltration was significantly associated with decreased disease-free survival (DFS; HR 5 1.65, 95% CI 1.34 to 2.03, p 5 0.000) in solid tumors. (Fig. 4) In stratified analyses by cancer types, as shown in Figure  S2 , we found that increased density of tryptase 1 mast cells within tumor was significantly associated with worse DFS in CRC (HR 5 1.75, 95% CI 1.36 to 2.26, p 5 0.000). Similar result was observed between tryptase 1 mast cell infiltration and DFS in HCC (HR 5 1.96, 95% CI 1.29 to 2.97, p 5 0.002).
We next investigated whether tumor-infiltrating tryptase 1 mast cell correlated with clinicopathological features such as lymph node metastasis, TNM stage, tumor differentiation, and vascular invasion of solid tumor. We found that tryptase 1 mast cell infiltration was significantly associated with lymph node metastasis (OR 5 1.57, 95% CI 1.08 to 2.28, (Fig. S3 ).
Sensitivity analysis
Sensitivity analyses were used to determine the influence of individual studies on the overall HR. As a result, the plot showed that all the individual studies had no important impact on the results for OS or DFS (Fig. S4) .
Publication bias
Funnel plot and Egger's test were performed to assess the publication bias of this meta-analysis. No publication bias existed between tryptase 1 mast cell infiltration and OS 
Discussion
Mast cells are traditionally implicated and well recognized in allergic reactions. In the last decades, although many studies have associated tumor-infiltrating tryptase 1 mast cells and and is angiogenic in vivo in the chorioallantoic membrane (CAM) assay. 40 Tryptase 1 mast cells can also synthesize and release other angiogenic factors including IL-8 and TNF-a as well as VEGF which promote the formation of blood vessels thereby facilitating tumor growth. 41 In addition, they can also secret amount of immunosuppressive cytokines such as TGFb1 and IL-10 to inhibit antitumor immunity mediated by effector T cells, recruit myeloid -derived suppressor cells (MDSC) via IL-17 A, CCL2 production and interact with regulatory T cells (Tregs) thus establishing immunosuppressive microenvironment. Furthermore, they can produce tryptase and matrix metalloproteinases (MMPs) including MMP-2 and MMP-9 to degrade extracellular matrix thereby facilitating tumor cell invasion of the stroma. 42 Thus, it is reasonable to speculate that the tryptase 1 mast cells are able to potentiate the deregulated tissue homeostasis of the tumor microenvironment (TME) and favor tumor growth and spread therefore decreasing survival. In the last decades, therapeutic strategies such as inhibition of recruitment of mast cells to the TME and blockade of pro-tumoral and pro-angiogenic effects have been applied in preclinical studies. And lots of pharmacological agents such as omalizumab, imatinib, disodium cromoglycate, H1 receptors antagonists, steroids and non-steroidal anti-inflammatory drugs and so forth have been developed to modulate the functions of mast cells. They can either inhibit the synthesis of mediators of mast cells, block the mediator receptors on target cells or inhibit mast cell activation. However, none of these agents could solely, and selectively suppress the function of mast cells, 43 suggesting that novel strategy targeting mast cells through specific markers directly such as "tryptase" may be effective to selectively deactivate or even eliminate them thereby preventing tumor growth.
Some limitations should be noted from this meta-analysis. First, morphometric analyses for tryptase 1 mast cells used in included studies were not consistent. Second, there was only one study reporting the relevant data for OS in several types of cancer, thus, we couldn't get a combined result for them. Finally, studies with negative results or small sample size may not be published, which can cause potential publication bias.
In conclusion, tryptase 1 mast cell infiltration leads to an unfavorable clinical outcome of patients with solid tumor, implicating that it is a valuable biomarker for prognostic prediction for human solid malignances and targeting it may have a potential for effective treatment. 
